Urologic oncology concerns the surgical treatment of malignant genitourinary diseases such as cancer of the prostate, adrenal glands, bladder, kidneys, ureters, testicles, and penis. The treatment of genitourinary cancer is managed by either a urologist or an oncologist, depending on the treatment type (surgical or medical). Most urologic oncologists in western countries use minimally invasive techniques (laparoscopy or endourology, robotic-assisted surgery, pelvic surgery) to manage urologic cancers amenable to surgical management. The Urologic Oncology Branch conducts clinical and basic research designed to develop better methods for detecting, preventing, and treating patients with kidney cancer, prostate cancer Urothelial cancer, Penile cancer and bladder cancer . It evaluates and manages the patients with non-inherited as well as inherited forms of kidney cancer. Patients with known or suspected localized and locally advanced prostate cancer undergo advanced MRI imaging followed by fusion image-guided biopsy to diagnose and characterize the cancer. They may then be managed with robotic surgery or be followed with active surveillance and intermittent imaging. In addition, we have a growing program in genomics and targeted therapy for bladder cancer patients, including therapy that targets EGFR, FGFR3 and other mutated bladder cancer genes.
A subspecialty clinic in Uro-oncology is a unique venture in India. Being a research institute with state-of-the-art infrastructure, we have highly focused team for the care of urological cancers. In cases where multimodality treatment is required, our institution has medical oncologists, radiation oncologists, state-of-the-art radiology, pathology and nuclear medicine departments, all under one roof. There are facilities for brachytherapy, conformal radiotherapy, Intensity-Modulated Radiation Therapy (IMRT) and therapeutic nuclear medicine procedures. The Uro-oncologists, radiation oncologists, medical oncologists and Uro-pathologists discuss the cases and make combined decisions on the management of all the cases at the Tumour Board. Follow up and further management are done as per the current protocols.